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Introduction: Although human papillomavirus (HPV) 
routine vaccination programmes have been imple-
mented around the world and recommendations have 
been expanded to include other high-risk individuals, 
current recommendations often differ between coun-
tries in Europe, as well as worldwide. Aim: To find and 
summarise the best available evidence of HPV vacci-
nation in high-risk patients aiding clinicians and pub-
lic health workers in the day-to-day vaccine decisions 
relating to HPV in Spain. Methods: We conducted a 
systematic review of the immunogenicity, safety and 
efficacy/effectiveness of HPV vaccination in high-risk 
populations between January 2006 and June 2016. 
HPV vaccination recommendations were established 
with levels of evidence according to the Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) system. Results: A strong recom-
mendation about HPV vaccination was made in the fol-
lowing groups: HIV infected patients aged 9–26 years; 
men who have sex with men aged 9–26 years; women 
with precancerous cervical lesions; patients with con-
genital bone marrow failure syndrome; women who 
have received a solid organ transplant or hematopoi-
etic stem cell transplantation aged 9–26 years; and 
patients diagnosed with recurrent respiratory papil-
lomatosis. Conclusions: Data concerning non-routine 
HPV vaccination in populations with a high risk of HPV 
infection and associated lesions were scarce. We have 
developed a document to evaluate and establish evi-
dence-based guidelines on HPV vaccination in high-
risk populations in Spain, based on best available 
scientific evidence.
Introduction
Human papillomavirus (HPV) is the main cause of 
uterine cervical cancer (UCC) and its precursor lesions 
[1,2]. HPV can also be found in cancerous and precan-
cerous lesions of the vulva and vagina [3,4], penis [5] 
anus [6], oropharyngeal cancer [7], anogenital warts 
[8] and recurrent respiratory papillomatosis (RRP) [9]. 
Nearly 90% of all female genital HPV infections are 
transient and resolve on their own in the next 2 years 
[10]. Persistence of HPV happens in 10% of infected 
healthy women and 1% of them will develop neoplastic 
HPV-related lesions. In men, duration and persistence 
of HPV infections are shorter than in women [11].
The estimated impact of newly diagnosed cases of 
HPV-related disease is high around the world: annually 
there are 30.9 million cases of cervical precancerous 
lesions, 32 million cases of genital condylomata and 
630,000 cases of cancer (cervix, vagina, vulva, anus, 
penis, oropharyngeal, oral cavity and larynx) diag-
nosed [12,13].
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HPV vaccination is an effective primary intervention to 
prevent HPV infection and its associated disease bur-
den. Vaccination is used as part of a coordinated strat-
egy with quality screening programmes and treatment 
services in cervical cancer prevention [14]. Three HPV 
vaccines containing virus-like particles (VLPs) are cur-
rently available: the bivalent vaccine (VLPs of high-risk 
HPV genotypes 16 and 18) [15]; the quadrivalent vac-
cine (VLPs of genotypes 6, 11, 16 and 18) [16]; and the 
nonavalent vaccine (VLPs of genotypes 6, 11, 16, 18, 
31, 33, 45, 52 and 58) [17].
In the first decade of HPV vaccine use, the main strat-
egy worldwide was routine vaccination programmes 
for adolescent and young women. In Europe, according 
European Centre for Disease Control (ECDC) informa-
tion reviewed in 2018, routine vaccination is included in 
the national immunisation schedule in the majority of 
countries (n = 29, 93.5%) [18]. In some countries, vac-
cine recommendations were later extended to include 
specific high-risk groups as the United States (US) 
where three doses of HPV vaccine are recommended 
for: (i) females and males aged 9–26 years with pri-
mary or secondary immunocompromising conditions 
that may reduce cell-mediated or humoral immunity, 
(ii) men who have sex with other men (MSM), (iii) 
transgender persons aged 9–26 years, (iv) individu-
als not adequately vaccinated and, (v) children with a 
history of sexual abuse [19,20]. In Australia MSM and 
immunocompromised individuals are included [21] and 
in Canada individuals with abnormal cervical cytol-
ogy or a history of UCC and/or genital warts, MSM and 
immunocompromised individuals [22] are included too. 
Currently, no global European recommendations for 
specific groups are mentioned [18] but some countries 
have begun to develop programmes [23].
In clinical practice, there is growing interest in expand-
ing vaccine recommendations to patients at high-risk 
of HPV infection and development of related neo-
plasms. Currently, information on HPV vaccination 
for these high-risk populations is scarce and recom-
mendations for selective vaccination differ between 
countries in Europe. Several reasons may explain the 
lack of guidelines for vaccination in high-risk popula-
tions, including: heterogeneity in the definition e.g. 
age, sex, disease characteristics and variations in 
the risk of infection, persistence or malignancy; lim-
ited published clinical trial data (due to difficulties in 
conducting appropriately powered studies on vaccine 
immunogenicity, safety and efficacy in individuals with 
low-incidence diseases); and limitations associated 
with establishing recommendations for patient groups 
not included in the product label. Some of these issues 
can be viewed in the Supplementary material.
A guideline on HPV vaccination in high-risk individu-
als, based on the review of current evidence by an 
independent and multidisciplinary expert panel, was 
recently released by the Spanish Association of Cervical 
Pathology and Colposcopy [24]. This paper summa-
rises this evidence-base and process and depicts the 
guideline.
Methods
In October 2015, a steering committee was formed in 
Spain to compile this guideline after a rigorous review 
of the HPV-associated disease burden and a system-
atic review of studies investigating the immunogenic-
ity, safety and efficacy of HPV vaccination in high-risk 
populations. This committee consisted of 10 Spanish 
professionals including gynaecologists, epidemiolo-
gists, paediatricians, infectologists, haematologists, 
gastroenterologists and preventive medicine special-
ists with recognised expertise in the area.
Selection criteria
This review included both randomised controlled trials 
(RCT) and observational studies (e.g. cohort studies, 
case reports) that assessed the effects of HPV vaccina-
tion on high-risk groups.
Based on clinical expertise of the steering committee 
and published literature, the following groups were 
defined as individuals at high-risk of HPV infection and 
HPV-related disease and were included in the guideline 
on HPV vaccination in high-risk individuals (Box).
The interventions of interest were the bivalent 
(Cervarix), quadrivalent (Gardasil) and nonavalent 
(Gardasil 9) HPV vaccines. The outcomes of interest 
were the efficacy, effectiveness, immunogenicity and 
safety of HPV vaccines.
Studies that did not report original data e.g. editorials 
or reviews were excluded.
Box
Individuals at high risk of human papillomavirus 
infection and related diseases, Spain, January 2006–June 
2016 
• HIV infected patients
• MSM
• Inflammatory bowel disease patients
• Women with precancerous cervical lesions
• Patients with congenital bone marrow failure syndrome, 
primary immunodeficiency or survivors of childhood 
neoplasia
• Solid organ or haematopoietic stem cell transplant 
recipients
• Patients with immunosuppressive or biological treatment
• Patients with recurrent respiratory papillomatosis
HIV: Human immunodeficiency virus; HPV: human papillomavirus; 
MSM: men who have sex with men.
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Search strategy
An electronic search was carried out using PubMed 
to find studies published in English from January 
2006 to June 2016. The search terms were a combina-
tion of the names and synonyms of the different risk 
groups, the HPV vaccines and the outcomes of inter-
est. The details of the search strategies are presented 
in the Supplementary material.
All authors conducted unstructured electronic searches 
and reviewed their personal files for relevant published 
papers.
Selection process
Two authors (XMG and JARP) independently screened 
the titles and abstracts of the articles identified by 
the PubMed search and selected articles for full-text 
reading in accordance with the selection criteria. Full 
texts for the relevant references were independently 
evaluated by XMG and JARP to determine their inclu-
sion. Reference lists of included articles were screened 
to consider further potentially eligible studies (Figure). 
Any discrepancies in study selection were resolved by 
discussion between the reviewers until a consensus 
was reached.
The agreement between reviewers in the selection pro-
cess was computed using Stata/SE 14.2 for Windows 
(StataCorp LLC, College Station, Texas) and resulted 
in agreement of qualitative measures (Cohen’s 
Kappa = 0.98) [25].
Panel subgroups reviewed the initial literature search, 
selected references, evaluated evidence, drafted rec-
ommendations and summarised the evidence for each 
section. The content of the guideline was decided by 
the consensus panel; the evidence evaluation pro-
cess involved a systematic weighting of the quality 
of evidence and the grade of recommendation using 
the Infectious Diseases Society of America (IDSA) ver-
sion of the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system [26,27].
The developed guideline for Spain was reviewed and 
endorsed by several groups acknowledged at the end 
of the article.
Results
Human immunodeficiency virus (HIV) 
infection
The prevalence of HPV infection in individuals with 
HIV infection is high [28-30]. Within this population, 
the number of sexual partners increases the risk of 
infection and reinfection for multiple HPV genotypes 
and decreases the probability of HPV clearance [29]. 
Compared with the general population, the persistence 
of HPV in people living with HIV significantly increases 
the risk of HPV-related cancers and condylomata.
Three risk subgroups can be identified in the overall 
HIV-infected population: HIV-infected women, HIV-
infected men who have sex exclusively with women 
(MSW) and HIV-infected MSM. While UCC screening 
programmes and the improvement in HIV disease con-
trol have led to a decrease in the incidence of UCC in 
HIV-infected women, the incidence of anal cancer in 
this population is 30 per 100,000 person-years (US, 
1996–2007) [31], and the prevalence of condylomata is 
5–7% vs 1% in the general population (US, 1991–1998) 
[32,33]. In line with this, HIV-infected MSW in the US 
during 1996–2007 have an incidence of anal cancer 
that was significantly higher compared with men with-
out HIV infection (46 vs two/100,000 person-years) [31].
The prevalence of condylomata in HIV-infected MSW in 
Spain from 2005 to 2009 was 15% [34]. The incidence 
of anal cancer in the US during 1996–2007 is especially 
high in MSM with HIV (131/100,000 person-years; rate 
ratio = 80.3 compared with men without HIV) [31], and 
the prevalence of condylomata in HIV-infected MSM in 
Spain from 2005 to 2009 was 28% [34].
Figure 
Flowchart of literature selection for review of human 
papillomavirus vaccination in high-risk populations, 
Spain, January 2006–June 2016
PubMed search:
476 references retrieved
28 references selected for
full-text reading
22 studies selected for
inclusion
38 studies included
HIV-infection: references 35–43
Men who have sex with men: references 
44, 54–58
Inflammatory bowel disease: reference 69
Women with precancerous cervical lesions: 
references 79–81
Congenital bone marrow failure syndrome:
references 86,88
Solid organ or hematopoietic stem cell 
transplant: references 104–106
Immunosuppressive or biological treatment: 
references 115–119
Recurrent respiratory papillomatosis:
references 122, 125–132
16 studies selected
for inclusion from
the personal files
of the authors
448 references excluded
after screening the title and 
abstract
6 publications excluded after
full-text reading:
• Duplicate data/report: 2
• No original data (letter, 
editorial, review): 4
HIV: Human immunodeficiency virus.
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Rationale for recommendations
Nine papers of HPV vaccination in HIV population were 
selected [35-43]. Available data on the immunogenicity 
and safety of HPV vaccines in people with HIV infection 
support its use for the prevention of HPV-related can-
cers and genital warts; however, there are limited data 
on the efficacy of the vaccine (Supplementary material 
Table S1).
The efficacy results obtained in RCT of MSM [44] can-
not be generalised to the HIV population, since the 
characteristics of the included individuals (age 16–26 
years; ≤ 5 lifetime sexual partners; no history of sexu-
ally transmitted infections) differ from the majority of 
MSM with HIV seen in clinical practice. Prospective, 
RCT evaluating the efficacy of HPV vaccines in the 
prevention of recurrence in people with HIV receiving 
treatment for condylomata or premalignant lesions are 
ongoing [45-47].
Ideally, people with HIV who receive a HPV vaccine 
should be on antiretroviral treatment and have good 
immune-virological control at the time of vaccination.
Summary of previous guidelines or consensus 
recommendations
The European Acquired Immune Deficiency Syndrome 
(AIDS) Clinical Society guidelines recommend HPV vac-
cination in all individuals with HIV; however, they state 
that in situations where there is an established HPV 
infection, vaccine efficacy is questionable [48]. The US 
guidelines recommend vaccination for HIV females and 
males through age 26 years [19,20,49].
The 2013 IDSA clinical practice guideline for vaccina-
tion of the immunocompromised host, recommends 
the administration of three-dose of quadrivalent HPV 
(qHPV) vaccine for females and males with HIV aged 
11–26 years [27].
Recommendations in HIV patients
HPV vaccination is recommended in both male and 
female individuals with HIV from 9–26 years (quality 
of evidence: moderate; recommendation: strong). HIV-
positive people aged 26 years and older could also 
benefit from HPV vaccination (quality of evidence low; 
recommendation: weak). The use of any of the avail-
able vaccines is indicated, although the quadrivalent 
or nonavalent vaccines are preferred given the high 
prevalence of anogenital warts in these patients.
Men who have sex with men
MSM have a high risk of HPV infection and HPV-related 
disease than MSW [50], with the incidence of anal neo-
plasia being nearly 20 times higher in MSM [51]. The 
annual recurrence rate of high-grade anal lesions fol-
lowing treatment may be up to 50% [52]. Data from the 
US suggest that MSM have a higher rate of condyloma 
than women do, but a lower rate than MSW [53].
Rationale for recommendations
Six papers of HPV vaccination in MSM population were 
selected (Supplementary material Table S2). One study 
evaluated the immunogenicity, efficacy and safety of 
the qHPV vaccine against HPV in healthy males aged 
16–26 years [54]. Of the 4,065 men enrolled in the 
study, 602 were MSM. Antibody GMTs were lower in 
MSM vs MSW [55]. In MSM, the efficacy of the vaccine 
for prevention of persistent genital infection by any of 
the genotypes in the vaccine was 43.6%, while the effi-
cacy for the prevention of persistent anal infection by 
HPV 6, 11, 16 or 18 was 94.9% [44,54]. The vaccine was 
effective in preventing 77.5% of the high-grade squa-
mous intraepithelial lesions (HSIL)/anal intraepithelial 
neoplasia (AIN) secondary to HPV 6, 11, 16 or 18, and 
70.2% of the genital warts [44].
The qHPV vaccine has also been evaluated in MSM 
patients aged 26 years or older. It was effective in the 
prevention of anal condyloma in a study of 313 MSM 
without story of anal condyloma or with history of pre-
vious HPV-related anal condyloma who had been recur-
rence-free for at least 12 months (hazard ratio = 0.45; 
p < 0.05) [56]; it also reduced the incidence of HSIL (AIN) 
in another study of 202 MSM aged 18 years and older 
(83.7% of them aged over 30 years) who were treated 
for histologically confirmed HSIL (AIN) [57]. The recur-
rence rate of HSIL (AIN) in vaccinated MSM vs those not 
vaccinated was 10.2 vs 15.7 per 100 person-years [57].
One study assessed the immunogenicity and safety 
of the nonavalent vaccine vs placebo [58]. This trial 
included 313 MSM aged 16–26 years in addition to 
1,106 MSW and 1,101 women who had neither received 
previous HPV vaccination nor had history of HPV-
related lesions. The per-protocol analysis showed that, 
in MSM, the seroconversion rate for different HPV 
types was 99.5–100%; the GMTs in MSM were lower 
compared with MSW and women (ratio of 0.6–0.8 and 
0.7–0.9, respectively, depending on the genotype ana-
lysed) [58]. Data on the efficacy of HPV vaccination 
for prevention of lesions are not available. No specific 
data on the safety of HPV vaccines in the MSM popula-
tion were described in most of the studies evaluated.
Summary of previous guidelines or consensus 
recommendations
The Advisory Committee on Immunisation Practices 
(ACIP) recommends routine HPV vaccination for MSM 
aged 9–26 years, including transgender persons [20].
Recommendations in men who have sex with men
HPV vaccination is recommended in MSM aged 9–26 
years (quality of evidence: moderate; recommendation: 
strong). MSM aged 26 years and older may also benefit 
from HPV vaccination (quality of evidence: very low; 
recommendation: weak). The use of any of the avail-
able vaccines is indicated, although the quadrivalent 
or nonavalent vaccines are preferred given the high 
prevalence of anogenital warts in MSM.
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Inflammatory bowel disease
Treatment of inflammatory bowel disease IBD (Crohn’s 
disease and ulcerative colitis) often includes immu-
nosuppressants, which increase the risk of HPV 
persistence. Compared with patients not receiving 
immunosuppressive treatment, patients with IBD 
receiving azathioprine show a higher incidence of cuta-
neous warts and skin and genital herpes flares [59]. 
Although some studies have reported the development 
or worsening of genital condyloma in patients with IBD 
treated with anti-tumour necrosis factor (TNF) antibod-
ies such as infliximab and etanercept [60,61], other 
studies suggest no relationship between the use of TNF 
antibodies and persistent HPV infection [62].
Controversy remains regarding to the increased risk 
of HPV infection and UCC in patients with IBD vs the 
general population. A study of 40 patients with IBD 
showed a higher incidence of abnormal cervical cytol-
ogy in women with IBD compared with similar healthy 
controls (42% vs 7%; p < 0.001), and a higher incidence 
of lesions [63]. In this study, the use of immunosup-
pressants for at least 6 months was also associated 
to an increased risk of abnormal cytology (Odds ratio 
(OR): 1.5; 95% confidence interval (CI): 1.2–4.1; p value 
= 0.021) [63]. A study of 116 women with IBD showed an 
increased rate of abnormal cervical cytology [64], while 
a population-based study of patients with Crohn’s dis-
ease demonstrated an increased risk of UCC and dys-
plasia [65]. Another study showed an increased risk of 
both low-grade squamous intraepithelial lesions (LSIL), 
HSIL and UCC in patients with IBD vs a control group 
(incidence rate ratio for UCC in Crohn’s disease: 1.53; 
95% CI: 1.04–2.27) [66]. Case–control studies have not 
shown an increased risk of histological or cytological 
cervical abnormalities in women with IBD [67,68].
Rationale for recommendations
One paper of HPV vaccination in IBD population was 
selected (Supplementary material Table S3). One study 
investigating the profile of the qHPV vaccine in patients 
with IBD showed an adequate immunogenicity and 
safety profile [69]. Similar antibody titres were induced 
in patients with IBD and healthy controls, although 
49% of the IBD patients were receiving immunosup-
pressants and 51% were receiving anti-TNF antibodies. 
Some major adverse events were detected (exacerba-
tions of IBD (n  =  2), pneumonia (n  =  1), ovarian tor-
sion (n = 1), acute sinus pain (n = 1)), but none of them 
appeared to be related to HPV vaccination.
Summary of previous guidelines or consensus 
recommendations
All guidelines regarding prevention of opportunistic 
infections in patients with IBD recommend regular 
clinical screening and HPV vaccination, particularly in 
patients receiving immunosuppressants [70-73].
Recommendations in inflammatory bowel disease 
patients
HPV vaccination is recommended for women with 
IBD aged 9–26 years (quality of evidence: low; rec-
ommendation: weak). Although vaccination can be 
administered at any time, it is preferable to vaccinate 
at the time of diagnosis and before the use of immu-
nosuppressive or biological therapies, to ensure higher 
immunogenicity. There are no data supporting HPV 
vaccination in men with IBD.
Women with HPV infection and precancerous 
cervical lesions
In Spain, a large-scale study estimate that the preva-
lence of HPV infection is 13.4% and 7.9% in women 
aged 26–45 and 46–65 years, respectively, compared 
with 28.8% in women aged 18–25 years [74]. Rates of 
precancerous cervical lesions are reported between 
0.4 and 0.7%; the estimated number of women aged 
18 years or older with HSIL (CIN) in Spain is in the range 
of 54,087–92,423 [75].
Rationale for recommendations
A substantial proportion of adult women become 
infected with HPV, particularly genotypes 16 and 18. 
The probability of persistence increases with age, 
which consequently increases the risk of precancerous 
lesions or UCC developing. Women with precancerous 
cervical lesions have a 5–25% risk of recurrence and 
an increased risk of developing UCC compared with the 
general population [76]. This increased risk is mainly 
due to persistent HPV. Moreover, while in general the 
HPV infection clears after treatment, natural immunity 
does not provide complete protection against reactiva-
tion or reinfection by the same HPV genotype [75].
Three papers of HPV vaccination in women with 
HPV infection and precancerous cervical lesions 
were selected (Supplementary material Table S4). 
Precancerous lesions are generally diagnosed in 
women aged 25 years or older; data about HPV vaccina-
tion in this group of women are limited. However, a few 
studies focused on adult women and showed that both 
qHPV vaccine and the bivalent HPV vaccine are immu-
nogenic, effective and safe in this age group [77,78]. 
Immunisation with the qHPV vaccine resulted in 64.9% 
(95% CI: 20.1–86.3) efficacy in preventing new cervi-
cal lesions by any HPV genotype in treated women [79]. 
Another study of 737 women undergoing cervical coni-
sation showed that the qHPV vaccine was associated 
with a 65% reduction in HPV recurrence at 2 years, 
regardless of genotype (2.5% vs 7.2% recurrences in 
vaccinated and unvaccinated women, respectively) 
[80]. The post-treatment risk reduction of new lesions 
following bivalent vaccine immunisation in women with 
surgically treated cervical lesions was 88.2% (95% CI: 
14.8–99.7), regardless of genotype [81]. These studies 
demonstrate that HPV vaccination in women with cervi-
cal lesions who undergo treatment results in a signifi-
cant reduction in the risk of new lesions. No specific 
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safety data on the HPV vaccines in these populations 
was identified in any of the studies evaluated.
Summary of previous guidelines or consensus 
recommendations
In Spain, a consensus guideline from several scien-
tific societies recommends HPV vaccination in sexually 
active women. Because of the increased risk of HPV 
infection and increased persistence of infection with 
age in women with prior HPV infection and viral clear-
ance, the intention of this recommendation is to protect 
against reinfection and to reduce the risk of developing 
new lesions and UCC in women receiving treatment for 
cervical lesions [75].
Recommendations in women with HPV infection and 
precancerous cervical lesions
HPV vaccination is recommended in women undergo-
ing treatment for precancerous cervical lesions (qual-
ity of evidence: moderate; recommendation: strong). 
Patients with precancerous cervical lesions who have 
not yet been treated, may benefit from HPV vaccination 
(quality of evidence: low; recommendation: strong). 
Ideally, the vaccine should be administered early, 
either at diagnosis or before cervical conisation.
Congenital bone marrow failure syndrome, 
primary immunodeficiency or survivors of 
childhood neoplasia
Congenital bone marrow failure syndrome (CBMFS) is 
a group of heterogeneous diseases associated with 
inadequate blood cell production, constitutional mal-
formations and predisposition to cancer. Patients with 
Fanconi’s anaemia and dyskeratosis congenita, both 
congenital bone marrow failure syndromes, are at risk 
of gynaecological and head and neck squamous cell 
carcinomas [82]. The increased risk of cancer in these 
patients means that cancer prevention strategies are 
essential.
Certain primary immunodeficiency conditions, such as 
epidermodysplasia verruciformis, hyper-IgE syndrome, 
idiopathic CD4 lymphopaenia, GATA2 deficiency and 
Warts-hypogammaglobulinaemia, infections and mye-
lokathesis (WHIM) or Netherton’s syndrome, have the 
presence of cutaneous warts as one of the main clinical 
manifestations of the disease [83]. Patients with these 
conditions are more susceptible to persistent HPV 
infection because of an impaired immune response to 
the virus, an increased risk of extensive skin involve-
ment and a higher risk of precancerous cervical lesions 
progressing to malignancy.
Survivors of childhood, adolescent or young adult-
hood cancer e.g. Hematopoietic stem cell transplanta-
tion (HSCT) recipients, post-transplant survivors with 
chronic graft-vs-host disease receiving immunosup-
pressive therapy, individuals with a history of pelvic 
radiation and those with Hodgkin’s lymphoma, are also 
at risk of adverse outcomes associated with HPV infec-
tion [84]. In one US study, male and female long-term 
cancer survivors had 150% and 40% more HPV-related 
malignancies, respectively, than the general popula-
tion [85].
Rationale for recommendations
Two papers of HPV vaccination in CBMFS, primary 
immunodeficiency or survivors of childhood neopla-
sia were selected (Supplementary material Table S5). 
Patients with Fanconi’s anaemia and dyskeratosys con-
genita have a similar immune response to HPV vaccina-
tion to that of the general population [86].
While live-attenuated vaccines are not feasible in 
patients with primary immunodeficiency, inactivated 
or subunit vaccines are considered safe [87] and could 
play an important role in the prevention of both malig-
nancy and warts. Immunisation of a WHIM patient with 
the qHPV vaccine induced neutralising antibodies and 
a cellular immune response, indicating that patients 
with WHIM syndrome may benefit from HPV vaccination 
[88]. No safety data were reported in any of the studies 
analysed. Although most survivors of childhood neo-
plasia recover their immunity within 6 months of the 
end of chemotherapy or immunosuppressive therapy, 
the immunogenicity to HPV vaccines in this population 
is not well known so additional studies are needed.
Summary of previous guidelines or consensus 
recommendations
ACIP recommends routine HPV vaccination to primary 
immunodeficiency patients aged 9–26 years [20]. 
The Children’s Oncology Group recommends HPV vac-
cination for all female survivors of childhood cancer 
[89,90].
Recommendations in patients with congenital bone 
marrow failure syndrome, primary immunodeficiency 
or survivors of childhood neoplasia
HPV vaccination of patients with CBMFS is recom-
mended (quality of evidence: low; recommendation: 
strong).
HPV vaccination may benefit patients with primary 
immunodeficiency (quality of evidence: very low; rec-
ommendation: weak). The use of any of the available 
vaccines is indicated, although the quadrivalent or 
nonavalent vaccines are preferred given the high prev-
alence of anogenital warts in these patients.
Survivors of childhood neoplasia can benefit from HPV 
vaccination (quality of evidence: very low; recommen-
dation: weak).
Solid organ or haematopoietic stem cell 
transplantation
Patients who have undergone solid organ transplanta-
tion need life-long immunosuppressive therapy, which 
increases their risk of complications associated with 
persistent HPV infection. Studies have shown that 
immunosuppressed transplant recipients have an 
increased presence of HPV in the oral cavity, higher 
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prevalence of genital warts [91], high oncogenic HPV 
in squamous cell skin cancer [92], an increased risk of 
anal cancer [93-95] and UCC [96-98].
Patients who have undergone HSCT have an increased 
risk of developing solid organ cancer [99]. In some 
studies, this risk was double that of the general popu-
lation [100,101]. The increase in survival after HSCT has 
been associated with an increased prevalence of HSIL 
in these women [102,103].
Rationale for recommendations
Three papers of HPV vaccination in solid organ 
or haematopoietic stem cell transplantation were 
selected [104-106] (Supplementary material Table S6). 
Epidemiological data show a high risk of gynaecologi-
cal and other cancers in transplant recipients [102]. 
Limited data are available on the immunogenicity and 
efficacy of HPV vaccination in individuals who have 
undergone solid organ transplantation, and no infor-
mation exists for HSCT recipients.
Summary of previous guidelines or consensus 
recommendations
ACIP recommends routine HPV vaccination for those 
aged 9–26 years for transplant patients [20].
The 2013 Infectious Diseases Society of America (IDSA) 
clinical practice guideline for vaccination of the immu-
nocompromised host recommends that physicians 
consider the administration of three doses of HPV vac-
cine 6–12 months after HSCT for female patients aged 
11–26 years and qHPV vaccine for males aged 11–26 
years. The HPV vaccine series should also be adminis-
tered to solid organ transplant candidates aged 11–26 
years [27].
Recommendations in solid organ or haematopoietic 
stem cell transplant recipients
HPV vaccination is recommended in female transplant 
recipients aged 9–26 years (quality of evidence: low; 
recommendation: strong). Female patients aged 26 
years and older may also benefit from HPV vaccination, 
particularly those with chronic graft vs host disease 
following HSCT (quality of evidence: very low; recom-
mendation: weak). If possible, vaccination should be 
provided before solid organ transplantation and prefer-
ably before the use of immunosuppressive or biological 
therapies to ensure high immunogenicity. Vaccination 
is not recommended within 6 months post-transplan-
tation. Patients undergoing HSCT should be vaccinated 
6–12 months after transplantation, even if vaccinated 
beforehand.
Immunosuppressive or biological treatment
Immunosuppression is an important risk factor for cer-
vical HPV infection [107]. HPV has a predilection for 
epithelial cells and causes an abnormal proliferation 
of keratinocytes, which may manifest as benign warts 
or malignant neoplasms. The host immune response to 
HPV infection is initiated by cytokines and chemokines 
that are secreted by the virally stimulated keratinocyte. 
If the immune response is sufficient HPV lesions may 
regress, but this resolution of HPV lesions is not gener-
ally seen in the immunosuppressed patients resulting 
in severe, persistent and extensive manifestations of 
HPV disease [108]. Among patients undergoing thera-
peutic immunosuppression, evidence is restricted to 
some disease types e.g. systemic lupus erythemato-
sus (SLE) or juvenile idiopathic arthritis (JIA) and rarely 
stratified by therapeutic modality or dosage.
Some studies have shown an increase in the prevalence 
of HPV infection, dysplasia and premalignant lesions in 
patients with SLE and those with kidney failure under-
going haemodialysis [107,109]. A systematic review of 
studies in patients with SLE concluded that they are 
at higher risk of cervical dysplasia and precancerous 
lesions. However, most studies show a similar preva-
lence of UCC in patients with SLE compared with the 
general population [110]. A delay in HPV clearance and 
a greater persistence of infection and HPV-associated 
lesions in SLE patients could be explained by altera-
tions in the innate and adaptive immune response in 
this population [111]. However, the role of immunosup-
pressants as a predisposing factor to HPV-associated 
cervical lesions is unconfirmed [102,112].
TNF blockers are widely used to treat chronic inflam-
matory diseases. TNF plays an essential part in host 
defence and the immune response. Although uncom-
mon, cases of extensive cutaneous HPV lesions 
have been reported following TNF blocking therapy 
[61,113,114].
Rationale for recommendations
The high rates of HPV infection and associated lesions 
in immunocompromised individuals justify the need to 
consider vaccination in this population [107]. Although 
published data are limited to some groups of patients, 
evidence suggests that women with SLE are at an 
increased risk of developing HPV-related lesions. As 
SLE is an immune disorder that predominantly affects 
women, most subjects in studies evaluating the risk of 
HPV infection and lesions in SLE patients are women 
[110].
Five papers of HPV vaccination in patients with immu-
nosuppressive or biological treatment were selected. 
(Supplementary material Table S7) [115-119]. In the larg-
est study, administration of the qHPV vaccine resulted 
in similar seroconversion rates to the general popula-
tion 12 months post-vaccination [115]. Lower serocon-
version rates were seen in patients receiving treatment 
with prednisolone or mycophenolate mofetil. There 
were no safety issues or an increased risk of SLE flares 
seen with vaccination [115].
Two studies evaluating the immunogenicity and safety 
of HPV vaccines in JIA patients have been published 
[118,119]. One was a prospective cohort study includ-
ing 68 females aged 12–18 years with JIA who were 
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vaccinated with bivalent HPV vaccine. The vaccine 
showed a strong HPV 16/18-specific antibody response 
that was comparable with the response seen in healthy 
female adolescents; HPV-specific geometric mean 
concentrations (GMCs) were consistently lower in JIA 
patients. No effect of methotrexate or anti-TNF treat-
ment on the vaccine response was observed and no 
safety concerns were found [118]. Another prospective 
cohort study including 21 female patients with JIA aged 
12–25 years and 21 healthy controls immunised with 
bivalent HPV vaccine showed significantly lower HPV 
16 neutralising antibody titres in JIA patients than con-
trols, but no significant difference in HPV-18 antibody 
titres. Immunoresponse to the vaccine did not seem to 
be affected by the type of anti-rheumatic therapy the 
patients were receiving. The vaccine was safe and well 
tolerated [119].
At present, there are no published data from ran-
domised clinical trials on the efficacy, immunogenic-
ity or safety of HPV vaccination in patients receiving 
immunosuppressive and/or biological treatment.
Summary of previous guidelines or consensus 
recommendations
The evidence-based recommendations on vaccination 
in patients with autoimmune rheumatic diseases from 
the European League against Rheumatism specify that 
HPV vaccination should be considered in women with 
SLE aged less than 26 years [120].
ACIP recommends routine HPV vaccination for immuno-
suppressed patients aged 9–26 years [20].
The 2013 IDSA clinical practice guideline for vaccina-
tion of the immunocompromised host recommends 
HPV vaccination for females and males 11–26 years old 
with chronic inflammatory diseases on immunosup-
pressive medications [27].
Recommendations in patients receiving 
immunosuppressive or biological treatment
HPV vaccination is recommended in women receiving 
immunosuppressive and/or biological treatment aged 
9–26 years, in particular, women with SLE or JIA (qual-
ity of evidence: low; recommendation: weak). While the 
vaccine can be given at any time, administration before 
Table
Summary of recommendations regarding human papillomavirus vaccination in high-risk populations
High-risk population Summary and recommendations Quality of evidence
Recommendation 
strength
HIV infection
HPV vaccination is recommended in HIV patients through age 
26, regardless of gender Moderate Strong
HIV-positive patients aged ≥ 26 years may also benefit from 
HPV vaccination Low Weak
MSM
HPV vaccination in MSM through age 26 is recommended Moderate Strong
MSM aged ≥ 26 years may benefit from HPV vaccination Very Low Weak
IBD HPV vaccination is recommended in women with IBD through age 26 Low Weak
Women with premalignant 
cervical lesions
HPV vaccination is recommended in women treated for 
precancerous cervical lesions Moderate Strong
Women with untreatable intraepithelial lesions may benefit 
from HPV vaccination Low Strong
CBMFS HPV vaccination is recommended in patients with CBMFS Low Strong
Primary immunodeficiency Patients with primary immunodeficiency may benefit from HPV vaccination Very low Weak
Survivors of childhood neoplasia Survivors of childhood cancer may benefit from HPV vaccination Very low Weak
Solid organ transplantation or 
HSCT
HPV vaccination is recommended in women through age 26 
who have received a solid organ transplant or HSCT Low Strong
Female patients aged ≥ 26 years may benefit from HPV 
vaccination, particularly those with chronic graft-vs-host 
disease after HSCT
Very low Weak
Immunosuppressive or biological 
treatment
HPV vaccination is recommended in women receiving 
immunosuppressive and/or biological treatment through age 
26 (in particular women with SLE or JIA)
Low Weak
RRP HPV vaccination is recommended in patients diagnosed with RRP through age 26 Low Strong
CBMFS: congenital bone marrow failure syndrome; HIV: human immunodeficiency virus; HPV: human papillomavirus; HSCT: haematological 
stem cell transplantation; IBD: inflammatory bowel disease; JIA: juvenile idiopathic arthritis; MSM: men who have sex with men; RRP: 
recurrent respiratory papillomatosis; SLE: systemic lupus erythematosus.
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the use of immunosuppressive or biological therapies 
is preferable. There are no data supporting HPV vac-
cination in males receiving immunosuppressive or bio-
logical therapy.
Recurrent respiratory papillomatosis
Recurrent respiratory papillomatosis (RRP) is charac-
terised by the presence of multiple papilloma in the 
airway that cause obstructive symptoms such as short-
ness of breath, hoarseness or stridor [121]. The disease 
may occur in children (aged ≤ 17 years) or adults [9,122]. 
The incidence of both juvenile and adult forms of RRP 
is estimated at 3–7 per 100,000 individuals [123,124]. 
HPV infection is the cause of RRP, with genotypes 6 
and 11 present in 90–95% of cases [9].
Rationale for recommendations
Nine papers of HPV vaccination in patients with 
recurrent respiratory papillomatosis were selected 
(Supplementary material Table S8). No randomised 
clinical trials on the efficacy of HPV vaccine have been 
conducted in individuals with RRP. Several studies 
have investigated the effectiveness of the quadrivalent 
vaccine in both juvenile RRP [122,125-131] and adult 
RRP [122,126,130,132] Supplementary material Table 
S8). Vaccination-induced partial or complete remission 
in a substantial proportion of the RRP patients, and no 
remarkable adverse effects were reported.
Summary of previous guidelines or consensus 
recommendations
There are no guideline or consensus documents that 
specifically recommend HPV vaccination in patients 
with RRP.
Recommendations in patients with RRP
HPV vaccination is recommended in patients with RRP 
aged 9–26 years (quality of evidence: low; recommen-
dation: strong). Given the relationship of RRP to HPV 
genotypes 6 and 11, the use of the quadrivalent or 
nonavalent vaccine is recommended. Despite scarce 
data, the potential benefit should outweigh the risk 
of vaccination; therefore compassionate use may be 
considered in juvenile patients who are under the age 
indicated in the summary of product characteristics for 
the vaccine.
Summary of recommendations
Data concerning non-routine HPV vaccination in popu-
lations with a high risk of HPV infection and associ-
ated lesions are scarce, and recommendations differ 
between countries. The evidence-based recommen-
dations for HPV vaccination in high-risk populations 
conducted by an independent expert panel are summa-
rised in Table.
Conclusions
Systematic HPV vaccination is considered the most 
effective intervention for controlling the infection and 
preventing HPV-related disease burden. Along with 
other interventions, such as information, screening 
and treatment, HPV vaccination is crucial in the preven-
tion of uterine cervical cancer.
In all high-risk populations, based on the summary and 
recommendations, the quality of evidence was found 
to be very low to moderate. A strong recommenda-
tion about HPV vaccination was made in HIV infected 
patients aged 9–26 years; men who have sex with men 
aged 9–26 years; women with precancerous cervical 
lesions; patients with congenital bone marrow failure 
syndrome; women who have received a solid organ 
transplant or hematopoietic stem cell transplantation 
aged 9–26 years; and patients diagnosed with recur-
rent respiratory papillomatosis. In the rest of high-risk 
categories with only a weak recommendation (HIV-
positive patients aged ≥ 26 years, MSM aged ≥ 26, IBD, 
patients with primary immunodeficiency, survivors of 
childhood neoplasia, women who have received a solid 
organ transplant or hematopoietic stem cell transplan-
tation aged ≥26 years and patients in immunosuppres-
sive or biological treatment), the quality of evidence 
was low or very low. Further studies are needed.
Note
Author Xavier Castellsagué passed away 12 June 2016.
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